Perioperative Anticoagulant Management

Medical Clinics of North America

Volumn 93, Issue 5, 2009, Pages 1105-1121

  Grant, Paul J ^a   Brotman, Daniel J ^b   Jaffer, Amir K ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Heparin; Perioperative care; Risk factors; Venous thromboembolism; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; TINZAPARIN; VITAMIN K GROUP; WARFARIN;

ABDOMINAL CANCER; ABDOMINAL PAIN; ACUTE CHOLECYSTITIS; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; AORTA VALVE DISEASE; ATTENTION; BLEEDING; BREAST CANCER; CATARACT EXTRACTION; CEREBROVASCULAR ACCIDENT; CHEST TIGHTNESS; CLINICAL TRIAL; COLON CANCER; COMPREHENSION; COMPRESSION GARMENT; CONGESTIVE HEART FAILURE; CONSULTATION; DEEP VEIN THROMBOSIS; DYSPNEA; EPIDURAL CATHETER; EVENING DOSAGE; FEMALE; HEART ATRIUM FIBRILLATION; HEMICOLECTOMY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INDWELLING CATHETER; INFERIOR CAVA VEIN; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; KNOWLEDGE; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MASTECTOMY; NEPHRECTOMY; OBESITY; OSTEOARTHRITIS; PELVIS CANCER; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE; SURGICAL PATIENT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TREATMENT DURATION; VALVULAR HEART DISEASE; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; ASPIRIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POLYSACCHARIDES; RISK FACTORS; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 68049135874     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.05.002     Document Type: Review

References (61)

1. Dunn A.S., and Turpie A.G. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 163 8 (2003) 901-908
2. Konstantatos A. Anticoagulation and cataract surgery: a review of the current literature. Anaesth Intensive Care 29 1 (2001) 11-18
3. Eisen G.M., Baron T.H., Dominitz J.A., et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 55 7 (2002) 775-779
4. Wahl M.J. Dental surgery in anticoagulated patients. Arch Intern Med 158 15 (1998) 1610-1616
5. Billingsley E.M. Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents. A prospective study. Dermatol Surg 23 5 (1997) 381-383 [discussion: 384-5]
6. Thumboo J., and O'Duffy J.D. A prospective study of the safety of joint and soft tissue aspirations and injections in patients taking warfarin sodium. Arthritis Rheum 41 4 (1998) 736-739
7. Lanzat M., Danna A.T., and Jacobson D.S. New protocols for perioperative management of podiatric patients taking oral anticoagulants. J Foot Ankle Surg 33 1 (1994) 16-20
8. Frazee L.A., Bourquet C.C., Gutierrez W., et al. Retrospective evaluation of a method to predict fresh-frozen plasma dosage in anticoagulated patients. Am J Ther 15 2 (2008) 111-118
9. Shields R.C., McBane R.D., Kuiper J.D., et al. Efficacy and safety of intravenous phytonadione (vitamin K1) in patients on long-term oral anticoagulant therapy. Mayo Clin Proc 76 3 (2001) 260-266
10. Crowther M.A., Donovan D., Harrison L., et al. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 79 6 (1998) 1116-1118
11. Weibert R.T., Le D.T., Kayser S.R., et al. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 126 12 (1997) 959-962
12. White R.H., McKittrick T., Hutchinson R., et al. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 122 1 (1995) 40-42
13. Crowther M.A., Douketis J.D., Schnurr, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 137 4 (2002) 251-254
14. Dezee K.J., Shimeall W.T., Douglas K.M., et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 166 4 (2006) 391-397
15. Douketis J.D., Berger P.B., Dunn A.S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 299S-339S
16. Bonow R.O., Carabello B.A., Chatterjee K., et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Valvular Heart Disease). American College of Cardiology Web Site. Available at:. http://www.acc.org/clinical/guidelines/valvular/index.pdf Accessed December 20, 2008
17. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991) 983-988
18. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001) 2864-2870
19. White R.H., Kaatz S., Douketis J., et al. Comparison of the 30-day incidence of ischemic stroke and bleeding after major surgery in patients with or without atrial fibrillation (AF). J Thromb Haemost 5 Suppl 1 (2007) O-M-035
20. Cerebral Embolism Task Force. Cardiogenic brain embolism. Arch Neurol 43 1 (1986) 71-84
21. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. [erratum appears in Arch Intern Med 1994;154(19):2254]. Arch Intern Med 154 13 (1994) 1449-1457
22. Bettadapur M.S., Griffin B.P., and Asher C.R. Caring for patients with prosthetic heart valves. Cleve Clin J Med 69 1 (2002) 75-87
23. Cannegieter S.C., Rosendaal F.R., and Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 89 2 (1994) 635-641
24. Jaffer A.K., Brotman D.J., and Chukwumerije N. When patients on warfarin need surgery. Cleve Clin J Med 70 11 (2003) 973-984
25. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (2008) 381S-453S
26. Hirsh J., Dalen J., Anderson D.R., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 1 Suppl (2001) 8S-21S
27. Warkentin T.E., Levine M.N., Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 20 (1995) 1330-1335
28. Spyropoulos A.C., Frost F.J., Hurley J.S., et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 125 (2004) 1642-1650
29. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl (2004) 188S-203S
30. O'Donnell M.J., Kearon C., Johnson J., et al. Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 146 3 (2007) 184-187
31. Anticoagulation in Prosthetic Valves and Pregnancy Consensus Report Panel and Scientific Round Table Discussion. Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy. Volume 3. Clinical cardiology consensus reports (2002), American Health Consultants, Atlanta (GA) 1-20
32. Tinker J.H., and Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 239 (1978) 738-739
33. Katholi R.E., Nolan S.P., and McGuire L.B. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 92 (1976) 162-167
34. Katholi R.E., Nolan S.P., and McGuire L.B. The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J 96 (1978) 163-165
35. Zhan C., and Miller M.R. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 290 (2003) 1868-1874
36. Shojania K.G., Duncan B.W., McDonald K.M., et al. Making health care safer: a critical analysis of patient safety practices; evidence report/technology assessment, No. 43 (prepared by the University of California at San Francisco-Stanford Evidence-based Practice Center under contract no. 290-97-0013). AHRQ Publication No. 01-E058, Rockville, MD. Agency for Healthcare Research and Quality. Available at:. www.ahrq.gov/clinic/ptsafety/ Accessed November 9, 2008
37. Clagett G.P., and Reisch J.S. Prevention of venous thromboembolism in general surgical patients: results of meta-analysis. Ann Surg 208 (1988) 227-240
38. Kudsk K.A., Fabian T.C., Baum S., et al. Silent deep vein thrombosis in immobilized multiple trauma patients. Am J Surg 158 (1989) 515-519
39. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 Suppl 3 (2004) 338S-400S
40. Cohen A.T., Tapson V.F., Bergmann J.F., et al. ENDORSE investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. [erratum appears in Lancet 2008;371(9628):1914]. Lancet 371 9610 (2008) 387-394
41. Mismetti P., Laporte S., Darmon J.Y., et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88 7 (2001) 913-930
42. Anderson Jr. F.A., and Spencer F.A. Risk factors for venous thromboembolism. Circulation 107 23 Suppl 1 (2003) I9-16
43. Jaffer A.K., Barsoum W.K., Krebs V., et al. Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. Mayo Clin Proc 80 6 (2005) 732-738
44. Amaragiri S.V., and Lees T.A. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 3 (2000) CD001484
45. Freedman K.B., Brookenthal K.R., Fitzgerald Jr. R.H., et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 82 7 (2000) 929-938
46. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355 (2000) 1295-1302
47. Gent M., Hirsh J., Ginsberg J.S., et al. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 93 1 (1996) 80-84
48. Collins R., Scrimgeour A., Yusuf S., et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 318 18 (1988) 1162-1173
49. Mismetti P., Laporte S., Zufferey P., et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2 7 (2004) 1058-1070
50. Brotman D.J., Jaffer A.K., Hurbanek J.G., et al. Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. Thromb Haemost 92 5 (2004) 1012-1017
51. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 6 (2008) 141S-159S
52. Turpie A.G., Bauer K.A., Eriksson B.I., et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162 16 (2002) 1833-1840
53. Agnelli G., Bergqvist D., Cohen A.T., et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 10 (2005) 1212-1220
54. Hull R.D., Pineo G.F., Stein P.D., et al. Extended out-of hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 135 (2001) 858-869
55. O'Donnell M., Linkins L.A., Kearon C., et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: a systematic review. Arch Intern Med 163 (2003) 1362-1366
56. Bergqvist D., Agnelli G., Cohen A.T., et al., for the ENOXACAN II investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
57. Horlocker T.T., Wedel D.J., Benzon H., et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA consensus conference on neuraxial anesthesia and anticoagulation). Reg Anesth Pain Med 28 (2003) 172-197
58. Offner P.J., Hawkes A., Madayag R., et al. The role of temporary inferior vena cava filters in critically ill surgical patients. Arch Surg 138 6 (2003) 591-594
59. Velmahos G.C., Kern J., Chan L.S., et al. Prevention of venous thromboembolism after injury: an evidence-based report; part II. Analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 49 (2000) 140-144
60. McMurty A.L., Owings J.T., Anderson J.T., et al. Increased use of prophylactic vena cava filters in trauma patients failed to decrease overall incidence of pulmonary embolism. J Am Coll Surg 189 (1999) 314-320
61. Fisher C.G., Blachut P.A., Salvian A.J., et al. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomized study of compression alone versus no prophylaxis. J Orthop Trauma 9 (1995) 1-7